Clinicopathological features | TGCT patients (n = 122) |
---|---|
Median age, years (IQR) | 28 (24–36) |
Histological type | |
 Seminoma | 56/122 (45.9%) |
 Embryonal carcinoma | 5/122 (4.1%) |
 Postpubertal-type yolk sac tumor | 0/122 (0%) |
 Choriocarcinoma | 0/122 (0%) |
 Postpubertal-type teratoma | 3/122 (2.5%) |
 Mixed tumor | 58/122 (47.5%) |
Pathological stage | |
 I | 78/122 (63.9%) |
 II | 23/122 (18.9%) |
 III | 21/122 (17.2%) |
IGCCCG grouping (for metastatic disease) | |
 Good | 31/44 (70.5%) |
 Intermediate | 6/44 (13.6%) |
 Poor | 7/44 (15.9%) |
Clinicopathological features | Primary TGCT tumor samples (n = 197) |
---|---|
Histological type | |
 Seminoma | 75/197 (38.0%) |
 Embryonal Carcinoma | 39/197 (19.8%) |
 Postpubertal-type yolk sac tumor | 35/197 (17.8%) |
 Choriocarcinoma | 12/197 (6.1%) |
 Postpubertal-type teratoma | 36/197 (18.3%) |
Clinicopathological features | Metastatic TGCT tumor samples (n = 19) |
---|---|
Histological type | |
 Seminoma | 1/19 (5.3%) |
 Embryonal carcinoma | 5/19 (26.3%) |
 Postpubertal-type yolk sac tumor | 3/19 (15.8%) |
 Choriocarcinoma | 1/19 (5.3%) |
 Postpubertal-type teratoma | 9/19 (47.3%) |
Type of metastasis | |
 Lymph node | 12/19 (63.2%) |
 Visceral | 7/19 (36.8%) |